DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis.

@article{Mey2006DHAPIC,
  title={DHAP in combination with rituximab vs DHAP alone as salvage treatment for patients with relapsed or refractory diffuse large B-cell lymphoma: a matched-pair analysis.},
  author={Ulrich J. M. Mey and Attilio Olivieri and Katjana S Orlopp and Christian Rabe and John W. Strehl and Marcus Gorschlueter and Manfred Hensel and Dimitri Flieger and Axel G Glasmacher and Ingo G. H. Schmidt-Wolf},
  journal={Leukemia & lymphoma},
  year={2006},
  volume={47 12},
  pages={2558-66}
}
The addition of rituximab to chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL) has been shown to improve outcome in first-line therapy. However, in patients with relapsed or refractory disease, the value of adding rituximab to salvage chemotherapy is less clearly defined. This study performed a matched-pair analysis of patients with relapsed or refractory DLBCL by comparing the combination of dexamethasone, high-dose cytarabine and cisplatin (DHAP) with rituximab to DHAP alone… CONTINUE READING